Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Food Allergenic Extract [EPC]
Carya Laciniosa Bark is a non-standardized allergenic extract used in the diagnosis and treatment of specific hypersensitivity reactions. It belongs to the class of plant-derived biological extracts used primarily in immunotherapy.
Name
Carya Laciniosa Bark
Raw Name
CARYA LACINIOSA BARK
Category
Non-Standardized Food Allergenic Extract [EPC]
Drug Count
5
Variant Count
5
Last Verified
February 17, 2026
About Carya Laciniosa Bark
Carya Laciniosa Bark is a non-standardized allergenic extract used in the diagnosis and treatment of specific hypersensitivity reactions. It belongs to the class of plant-derived biological extracts used primarily in immunotherapy.
Detailed information about Carya Laciniosa Bark
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Carya Laciniosa Bark.
Carya Laciniosa Bark, derived from the Shellbark Hickory tree, is a biological substance classified as a Non-Standardized Plant Allergenic Extract [EPC]. In the realm of clinical pharmacology, this substance is utilized primarily within the field of allergy and immunology. Unlike standardized extracts, which have a defined potency measured by specific biological units (such as Bioequivalent Allergy Units or BAU), Carya Laciniosa Bark is prepared according to traditional weight-to-volume (w/v) ratios or PNU (Protein Nitrogen Unit) concentrations. This extract is a complex mixture of proteins, glycoproteins, and polysaccharides harvested from the bark of the Carya laciniosa species, a member of the Juglandaceae family native to North America.
According to the FDA’s Center for Biologics Evaluation and Research (CBER), allergenic extracts like Carya Laciniosa Bark are indicated for the skin test diagnosis of patients with a history of allergy to hickory or related species and for use in allergen immunotherapy (AIT). Immunotherapy is a disease-modifying treatment that aims to desensitize the patient's immune system to specific environmental or food-based allergens. Carya Laciniosa Bark belongs to a class of drugs called allergenic extracts, which are unique because they do not target a specific receptor in the traditional sense but rather modulate the entire immune response toward a specific protein profile.
The mechanism of action for Carya Laciniosa Bark extract involves a sophisticated modulation of the human immune system, specifically targeting the Type I hypersensitivity pathway. When a patient is allergic to hickory components, their immune system produces specific Immunoglobulin E (IgE) antibodies that bind to mast cells and basophils. Upon subsequent exposure, the allergen cross-links these IgE antibodies, triggering the release of inflammatory mediators like histamine, leukotrienes, and cytokines.
In a clinical setting, Carya Laciniosa Bark is used in 'Allergen Immunotherapy' (AIT). The process works through several distinct immunological phases:
The pharmacokinetics of allergenic extracts like Carya Laciniosa Bark differ significantly from small-molecule drugs. Because these are biological proteins, they do not follow traditional absorption, distribution, metabolism, and excretion (ADME) patterns.
Carya Laciniosa Bark extract is FDA-approved for the following clinical indications:
Off-label uses are rare but may include research into cross-reactivity between different members of the Juglandaceae family (such as pecans and walnuts), as these species often share homologous proteins.
Carya Laciniosa Bark is available in the following formulations:
> Important: Only your healthcare provider can determine if Carya Laciniosa Bark is right for your specific condition. The administration of this extract must always be performed under the supervision of a physician equipped to treat systemic allergic reactions.
Dosage for Carya Laciniosa Bark is highly individualized and must be determined by an allergist based on the patient's sensitivity level. There is no 'standard' dose for all patients.
During the initial phase, the dose starts very low (e.g., 0.05 mL of a 1:10,000 w/v dilution). Injections are typically given 1 to 3 times per week. The dose is gradually increased by 0.05 mL to 0.1 mL increments until the 'Maintenance Dose' is reached. This phase usually lasts 3 to 6 months.
Once the maintenance dose is reached (often 0.5 mL of a 1:10 or 1:20 w/v solution), the frequency of injections is decreased to once every 2 to 4 weeks. This phase is maintained for 3 to 5 years to ensure long-term immunological tolerance.
Carya Laciniosa Bark is generally considered safe for pediatric use in children over the age of 5. Dosing follows the same build-up and maintenance logic as adult dosing, though smaller increments may be used for highly sensitive children. Use in children under 5 requires extreme caution due to the difficulty of the child communicating early symptoms of a systemic reaction.
No specific dose adjustments are required for renal impairment, as the proteins are metabolized by proteases. However, the patient's overall health must be stable.
No dose adjustments are documented for hepatic impairment.
Caution is advised in elderly patients (over 65) due to the higher prevalence of underlying cardiovascular disease. If an elderly patient requires epinephrine for an accidental reaction, their heart may be less able to tolerate the stress of the medication.
Carya Laciniosa Bark extract is administered via subcutaneous injection (under the skin), usually in the posterior aspect of the upper arm.
If a dose is missed during the build-up phase, the next dose may need to be reduced or the previous dose repeated to ensure safety. If a maintenance dose is missed by more than 2 weeks, the physician may reduce the dose for the next injection to prevent a reaction. Never 'double up' on doses.
An overdose of Carya Laciniosa Bark results in a systemic allergic reaction or anaphylaxis. Signs include:
Emergency Measures: Immediate administration of epinephrine (1:1000), followed by antihistamines, corticosteroids, and emergency transport to a hospital.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Ensure your provider is aware of any new medications or changes in your health status before each injection.
Local reactions at the injection site are the most frequent side effect of Carya Laciniosa Bark immunotherapy. These are generally considered a sign that the immune system is responding to the treatment.
> Warning: Stop taking Carya Laciniosa Bark and call your doctor immediately if you experience any of these symptoms of anaphylaxis.
There are no known systemic 'long-term' toxicities associated with Carya Laciniosa Bark, as it is a biological protein. However, the primary long-term risk is the development of Eosinophilic Esophagitis (EoE), a condition where white blood cells build up in the esophagus. While more common with oral immunotherapy, patients on subcutaneous shots should report any new or worsening difficulty swallowing (dysphagia).
Carya Laciniosa Bark, like all allergenic extracts, carries a stringent warning regarding Anaphylaxis.
Summary of Warning:
Report any unusual symptoms to your healthcare provider. Even a 'large' local reaction should be reported, as it may predict a future systemic reaction.
Carya Laciniosa Bark is a potent biological agent. Its use is restricted to patients with a confirmed IgE-mediated allergy. It is not a general 'tonic' or supplement for health; it is a specific medical treatment for desensitization. Patients must be in good health at the time of each injection. If you have a fever, respiratory infection, or are experiencing an acute asthma flare, your injection must be postponed.
No FDA black box warnings for Carya Laciniosa Bark are listed in the same format as pharmaceutical drugs, but the 'General Warnings' section of the prescribing information functions as a black box warning. It emphasizes that allergenic extracts can cause severe, life-threatening anaphylaxis. The risk is highest during the build-up phase or when switching to a new vial of extract (even of the same concentration).
Generally, Carya Laciniosa Bark does not cause sedation. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until they are fully recovered and cleared by a physician.
Alcohol should be avoided for several hours before and after the injection. Alcohol causes vasodilation (widening of blood vessels), which can increase the rate of allergen absorption and potentially trigger a more severe reaction.
Immunotherapy is usually discontinued if the patient experiences a life-threatening reaction or if there is no significant improvement in symptoms after 12-24 months of maintenance therapy. There is no 'withdrawal' syndrome, but stopping early will result in the return of allergy symptoms.
> Important: Discuss all your medical conditions with your healthcare provider before starting Carya Laciniosa Bark.
Mechanism of Interactions:
Most interactions with Carya Laciniosa Bark are pharmacodynamic. They do not change the level of the bark extract in the blood, but they change how the body responds to the extract or how the body responds to the emergency medications used to treat a reaction.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
Carya Laciniosa Bark must NEVER be used in the following circumstances:
These conditions require a careful risk-benefit analysis by the allergist:
Patients allergic to Carya Laciniosa Bark are highly likely to be cross-sensitive to other members of the Carya genus (like Pecan - Carya illinoinensis) and the Juglans genus (Walnut). Caution should be used if the patient is being tested or treated with multiple extracts from the Juglandaceae family simultaneously, as the cumulative dose of shared proteins could trigger a reaction.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Carya Laciniosa Bark.
Pregnancy Category C: Carya Laciniosa Bark has not been studied in pregnant women.
It is generally considered safe to continue Carya Laciniosa Bark immunotherapy while breastfeeding. The large protein molecules in the extract are not expected to pass into breast milk in any significant quantity, and if they did, they would be digested by the infant's stomach.
Patients over 65 are at higher risk for complications from immunotherapy. This is not because the extract works differently, but because older adults are more likely to have underlying heart disease or be taking medications like beta-blockers or ACE inhibitors that make a systemic reaction more dangerous.
No specific studies have been conducted. However, since the extract consists of proteins that are broken down into amino acids, renal impairment is not considered a contraindication or a reason for dose adjustment.
No dosage adjustments are required. The liver is not the primary site of clearance for these biological proteins.
> Important: Special populations require individualized medical assessment. Always inform your allergist if you become pregnant or develop new health conditions during the course of your treatment.
Carya Laciniosa Bark extract acts as a biological response modifier. Its primary molecular target is the T-lymphocyte. Specifically, it induces the production of Regulatory T-cells (Tregs). These cells secrete Interleukin-10 (IL-10) and Transforming Growth Factor-beta (TGF-β), which inhibit the Th2-mediated allergic cascade. Furthermore, the extract promotes a 'class switch' in B-lymphocytes, moving from the production of Allergen-specific IgE to Allergen-specific IgG4. IgG4 serves as a competitive inhibitor, binding to the hickory proteins before they can reach the IgE on the surface of mast cells.
| Parameter | Value |
|---|---|
| Bioavailability | N/A (Subcutaneous) |
| Protein Binding | N/A (Local immune uptake) |
| Half-life | Hours (Proteins), Years (Immune memory) |
| Tmax | 1-2 hours (Systemic absorption) |
| Metabolism | Proteolysis (Proteases) |
| Excretion | Renal (Metabolites) |
Carya Laciniosa Bark is a Non-Standardized Plant Allergenic Extract. It is grouped with other deciduous tree extracts like Oak, Maple, and Birch. It is distinct from 'Standardized' extracts like Grass or Dust Mite, which have more rigorous potency testing requirements.
Common questions about Carya Laciniosa Bark
Carya Laciniosa Bark extract is primarily used for the diagnosis and treatment of allergies to Shellbark Hickory. In diagnostic settings, it is used in skin prick testing to identify if a patient has an IgE-mediated sensitivity to the tree's proteins. For treatment, it is used in allergen immunotherapy, commonly known as allergy shots. This process involves giving gradually increasing doses of the extract to desensitize the immune system. Over time, this reduces symptoms of allergic rhinitis and asthma caused by hickory exposure.
The most common side effects are local reactions at the site of the injection, occurring in a majority of patients. These include redness, swelling, itching, and a firm lump or 'wheal' where the needle entered the skin. These reactions usually appear within minutes and resolve within 24 to 48 hours. Occasionally, patients may experience mild systemic symptoms like sneezing or a slight headache. While common, these local effects are generally not dangerous but should be reported to your doctor.
It is strongly recommended to avoid alcohol consumption on the day of your Carya Laciniosa Bark injection. Alcohol causes vasodilation, which increases blood flow to the skin and can cause the injected allergen to be absorbed into your bloodstream more rapidly. This increased absorption rate significantly raises the risk of a systemic allergic reaction or anaphylaxis. Furthermore, alcohol can impair your ability to recognize early warning signs of a reaction. Always wait at least 24 hours after an injection before consuming alcohol.
Carya Laciniosa Bark immunotherapy is generally not started during pregnancy due to the risk of anaphylaxis, which can deprive the fetus of oxygen. However, if a woman is already on a stable maintenance dose and becomes pregnant, many allergists allow the treatment to continue. The dosage is typically not increased during pregnancy to minimize the risk of a reaction. There is no evidence that the extract itself causes birth defects or harm to the baby. You must discuss your pregnancy immediately with your allergist to determine the safest course of action.
Allergen immunotherapy is a long-term treatment process and does not provide immediate relief like antihistamines do. Most patients begin to notice a reduction in their allergy symptoms within 6 to 12 months of starting the treatment. Significant improvement usually occurs once the maintenance dose is reached. For the best and most lasting results, the treatment must be continued for 3 to 5 years. Stopping the treatment too early may result in the return of symptoms.
Yes, you can stop taking Carya Laciniosa Bark injections suddenly without experiencing physical withdrawal symptoms. Unlike some medications, allergenic extracts do not create a chemical dependency in the body. However, stopping the treatment before the recommended 3-to-5-year course is complete will likely result in the loss of the 'tolerance' your immune system has built up. This means your allergy symptoms will eventually return to their original severity. Always consult your allergist before deciding to discontinue your immunotherapy.
If you miss a scheduled injection, you should contact your allergist's office as soon as possible to reschedule. Do not attempt to 'make up' the dose by taking more later. Depending on how much time has passed since your last injection, your doctor may need to reduce the dose for your next visit to ensure safety. Missing too many doses during the build-up phase may require you to restart the escalation process from a lower concentration. Consistency is key to the success of immunotherapy.
There is no clinical evidence to suggest that Carya Laciniosa Bark extract causes weight gain. The extract consists of a very small amount of protein and does not contain hormones or metabolic-altering chemicals. If you experience weight changes while on immunotherapy, it is likely due to other factors such as lifestyle changes or other medications you may be taking (like oral corticosteroids for asthma). Discuss any concerns about weight with your primary care physician.
Carya Laciniosa Bark can be taken with most common medications, but there are critical exceptions. You must avoid beta-blockers, as they prevent epinephrine from working in an emergency. You should also inform your doctor if you are taking ACE inhibitors or MAO antidepressants, as these can complicate the management of an allergic reaction. Most standard allergy medications, like Claritin or Flonase, are safe and often encouraged during the build-up phase of immunotherapy.
Carya Laciniosa Bark is a biological extract rather than a traditional pharmaceutical drug, so the term 'generic' does not apply in the usual way. However, various biological laboratories produce hickory bark extracts that are essentially equivalent. These are sold under different manufacturer names but are all non-standardized extracts of Carya laciniosa. Your allergist will select a high-quality extract from a reputable supplier, and the specific brand is less important than the concentration and purity of the extract.